Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310 is registered in ClinicalTrials.gov with Xenon Pharmaceuticals Inc. as lead sponsor.

NCT NCT04639310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04639310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy
Lead sponsor
Xenon Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
March 29, 2021
Completion date
May 16, 2023
Enrollment
8 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

brain diseases, central nervous system diseases, disease, epilepsy, epilepsy in children, epilepsy; seizure, epileptic syndromes, nervous system diseases